Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Computer-based continuing education courses may be effective in improving the skills of primary care doctors to identify skin cancer risk factors, perform skin cancer exams, and counsel patients. They may also improve the skills of primary care doctors to assess and counsel patients on their weight, diet, and physical activity.

PURPOSE: This randomized clinical trial is studying how well computer-based continuing education courses work in improving doctors' ability to perform skin cancer or weight control exams and counseling during routine office visits.


Clinical Trial Description

OBJECTIVES:

Primary

- Compare the efficacy of a continuing education course designed to improve primary care physician performance in examination and counseling of patients about skin cancer vs a continuing education course designed to improve physician assessment of weight management.

- Evaluate physician performance of skin examination during routine patient visits at 12 months after completion of the skin cancer continuing education course.

- Evaluate physician counseling around skin cancer issues.

Secondary

- Evaluate the efficacy of the skin cancer continuing education course in improving physician skin cancer triage skills and in changing physician attitudes and knowledge regarding skin cancer issues.

- Assess improvements in physician assessment of weight, diet, and physical activity.

OUTLINE: This is a randomized, multicenter study. Physicians are stratified according to participating center. Physicians are randomized to 1 of 2 intervention arms.

- Arm I (skin cancer continuing education course): Physicians complete a 1-hour continuing education course on skin cancer. The course is available to the physician as a reference for up to 12 months. Physicians complete an online test at baseline, immediately after the course is completed, and at 1 month and 12 months after course completion to assess their knowledge, attitudes, skill, and practices towards skin examination and skin cancer counseling.

Patients are interviewed by telephone within 1 week after a routine office visit with their physician to assess the physician's skin assessment and skin cancer counseling practices. The interviews are conducted prior to and at 1 month and 12 months after the physician completes the continuing education course.

- Arm II (weight control continuing education course): Physicians complete a 1-hour continuing education course on weight, dietary, and physical activity assessment and counseling. The course is available to the physician as a reference for up to 12 months. Physicians complete an online test at baseline, immediately after the course is completed, and at 1 month and 12 months after course completion to assess their knowledge, attitudes, skill, and practices towards weight, dietary, and physical activity assessment and counseling.

Patients are interviewed by telephone within 1 week after a routine office visit with their physician to assess the physician's weight, dietary, and physical activity assessment and counseling practices. The interviews are conducted prior to and at 1 month and 12 months after the physician completes the continuing education course.

PROJECTED ACCRUAL: A total of 50 physicians and 4,500 patients will be accrued for this study. ;


Study Design

Allocation: Randomized


Related Conditions & MeSH terms


NCT number NCT00295906
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Recruiting
Phase N/A
Start date June 2004

See also
  Status Clinical Trial Phase
Completed NCT04062032 - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma Phase 2
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Completed NCT00962845 - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery Early Phase 1
Completed NCT00324623 - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma Phase 1
Completed NCT00104845 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 1
Completed NCT00096382 - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00072124 - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Phase 3
Completed NCT00072085 - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00089193 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 2
Active, not recruiting NCT00039234 - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Phase 3
Completed NCT00042783 - Vaccine Therapy in Treating Patients With Stage IV Melanoma Phase 2
Completed NCT00049010 - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma N/A
Completed NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer Phase 1
Completed NCT00020358 - Vaccine Therapy in Treating Patients With Melanoma Phase 2
Completed NCT00006385 - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00005610 - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Phase 2
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Withdrawn NCT00006126 - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery Phase 1